• Clarivate guided FY 2026 revenue including discontinued ops to USD 2.3 billion-USD 2.42 billion, with the midpoint at about USD 2.35 billion.
• Organic ACV growth outlook set at 0.75%-2.25%, flagged for the lower half as Life Sciences & Healthcare shifts to discontinued ops in H2.
• Recurring organic revenue growth forecast at (4)% to 3%, with expectations for H2 acceleration on subscription growth and re-occurring revenue recovery.
• Adjusted EBITDA expected at about USD 980 million-USD 1.04 billion, with adjusted EBITDA margin at 42%-43.5%.
• Adjusted diluted EPS outlook at $0.7-$0.8; free cash flow expected at USD 365 million-USD 435 million, pressured by one-time transaction and cost-savings charges.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarivate plc published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.